Gary A Lyons

Gary A Lyons has an estimated net worth of $303 Million. This is based on reported shares across multiple companies, which include FACET BIOTECH CORP, NEUROCRINE BIOSCIENCES INC, NeurogesX Inc, Travere Therapeutics, Inc., RIGEL PHARMACEUTICALS INC, PONIARD PHARMACEUTICALS, INC., KALOBIOS PHARMACEUTICALS INC, CYTORI THERAPEUTICS, INC., Eledon Pharmaceuticals, Inc., Brickell Biotech, Inc., PDL BIOPHARMA, INC., and INTRABIOTICS PHARMACEUTICALS INC /DE.

2020 was Gary A Lyons's most active year for acquiring shares with 21 total transactions. Gary A Lyons's most active month to acquire stocks was the month of April. 2005 was Gary A Lyons's most active year for disposing of shares, totalling 50 transactions. Gary A Lyons's most active month to dispose stocks was the month of October. 2004 saw Gary A Lyons paying a total of $6,269,755.00 for 160,500 shares, this is the most they've acquired in one year. In 2025 Gary A Lyons cashed out on 31,435 shares for a total of $2,289,082.50, their largest year based on trade value.